Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 19 Colorectal Neoplasms 11 Brain Neoplasms 7 Colonic Neoplasms 5 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Rectal Neoplasms 2 Lung Neoplasms 2 Thyroid Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 37 Radiotherapy 20 Bevacizumab 14 Carboplatin 10 Magnetic Resonance Spectroscopy 9 Carmustine 9 antineoplaston AS 2-1 8 antineoplaston A10 8 Irinotecan 8 Filgrastim 7 Cyclophosphamide 6 Cisplatin 6 Etoposide 5 sargramostim 4 Vincristine 4 Thiotepa 4 Surgical Procedures, Operative 4 Specimen Handling 4 Radiation 4 Peripheral Blood Stem Cell Transplantation 4 Lomustine 4 Everolimus 4 Chemotherapy, Adjuvant 4 trametinib 3 aldesleukin 3 Topotecan 3 Thalidomide 3 Tamoxifen 3 Sunitinib 3 Procarbazine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Astrocytoma × encorafenib × Clear all

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡